TWI672503B - 致免疫性之癌症特異抗原決定位的排名系統 - Google Patents

致免疫性之癌症特異抗原決定位的排名系統 Download PDF

Info

Publication number
TWI672503B
TWI672503B TW107111453A TW107111453A TWI672503B TW I672503 B TWI672503 B TW I672503B TW 107111453 A TW107111453 A TW 107111453A TW 107111453 A TW107111453 A TW 107111453A TW I672503 B TWI672503 B TW I672503B
Authority
TW
Taiwan
Prior art keywords
peptide chain
epitope
major histocompatibility
histocompatibility complex
peptide
Prior art date
Application number
TW107111453A
Other languages
English (en)
Chinese (zh)
Other versions
TW201903411A (zh
Inventor
楊沛佳
鄭人豪
映嘉 陳
淑貞 陳
陳華鍵
Original Assignee
行動基因生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 行動基因生技股份有限公司 filed Critical 行動基因生技股份有限公司
Publication of TW201903411A publication Critical patent/TW201903411A/zh
Application granted granted Critical
Publication of TWI672503B publication Critical patent/TWI672503B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Data Mining & Analysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Artificial Intelligence (AREA)
TW107111453A 2017-03-31 2018-03-31 致免疫性之癌症特異抗原決定位的排名系統 TWI672503B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479320P 2017-03-31 2017-03-31
US62/479,320 2017-03-31

Publications (2)

Publication Number Publication Date
TW201903411A TW201903411A (zh) 2019-01-16
TWI672503B true TWI672503B (zh) 2019-09-21

Family

ID=63676910

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107111453A TWI672503B (zh) 2017-03-31 2018-03-31 致免疫性之癌症特異抗原決定位的排名系統

Country Status (7)

Country Link
US (1) US11485784B2 (https=)
EP (1) EP3600340A4 (https=)
JP (1) JP7155470B2 (https=)
CN (1) CN110799196B (https=)
SG (1) SG11201907738UA (https=)
TW (1) TWI672503B (https=)
WO (1) WO2018183980A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2729116C2 (ru) * 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
KR102841050B1 (ko) * 2017-04-19 2025-08-01 그릿스톤 바이오, 인코포레이티드 신생항원 동정, 제조, 및 용도
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
CA3115017C (en) * 2018-11-21 2023-10-31 Nec Corporation Method and system of targeting epitopes for neoantigen-based immunotherapy
AU2019404547B2 (en) * 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
WO2020174077A1 (en) 2019-02-28 2020-09-03 Universiteit Antwerpen Method for determining responsiveness to an epitope
US20220208306A1 (en) * 2019-04-30 2022-06-30 Memorial Sloan Kettering Cancer Center System and methods for identification of non-immunogenic epitopes and determining efficacy of epitopes in therapeutic regimens
CN115917654A (zh) * 2020-04-21 2023-04-04 瑞泽恩制药公司 用于分析受体相互作用的方法和系统
JP2024508677A (ja) * 2021-02-05 2024-02-28 アマゾン テクノロジーズ インコーポレイテッド 個別化がんワクチン用ネオアンチゲンのランク付け
US12518851B2 (en) * 2021-09-07 2026-01-06 Nec Corporation Binding peptide generation for MHC class I proteins with deep reinforcement learning for immunotherapy decision making
CN118302816A (zh) * 2021-09-28 2024-07-05 行动基因(智财)有限公司 甲基化生物标记选择装置及方法
WO2025217519A1 (en) * 2024-04-12 2025-10-16 Foundation Medicine, Inc. Clonal neoantigen burden as a biomarker of immunotherapy response

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160069895A1 (en) * 2014-09-10 2016-03-10 Genentech, Inc. Immunogenic mutant peptide screening platform

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005301523A (ja) * 2004-04-08 2005-10-27 Celestar Lexico-Sciences Inc ワクチン候補部分配列予測装置、ワクチン候補部分配列予測方法、ｍｈｃ結合部分配列予測装置、ｍｈｃ結合部分配列予測方法、プログラムおよび記録媒体
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN118750591A (zh) * 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
CN107750278B (zh) 2015-04-27 2023-10-03 癌症研究技术有限公司 治疗癌症的方法
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CN107704727B (zh) * 2017-11-03 2020-01-31 杭州风起智能科技有限公司 基于肿瘤新抗原特征值的新抗原活性预测和排序方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160069895A1 (en) * 2014-09-10 2016-03-10 Genentech, Inc. Immunogenic mutant peptide screening platform

Also Published As

Publication number Publication date
WO2018183980A3 (en) 2018-12-20
EP3600340A2 (en) 2020-02-05
US11485784B2 (en) 2022-11-01
TW201903411A (zh) 2019-01-16
JP7155470B2 (ja) 2022-10-19
CN110799196B (zh) 2024-02-13
SG11201907738UA (en) 2019-09-27
US20210284738A1 (en) 2021-09-16
EP3600340A4 (en) 2021-01-20
CN110799196A (zh) 2020-02-14
JP2020518083A (ja) 2020-06-18
WO2018183980A2 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
TWI672503B (zh) 致免疫性之癌症特異抗原決定位的排名系統
US20250316334A1 (en) Neoantigen identification, manufacture, and use
AU2019346023B2 (en) Method for selecting neoepitopes
US20180330055A1 (en) Neoantigen identification, manufacture, and use
US20210011026A1 (en) Reducing junction epitope presentation for neoantigens
Zhao et al. Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification
KR20250161050A (ko) 바이러스성 암 네오에피토프를 위한 조성물 및 방법
US20230047716A1 (en) Method and system for screening neoantigens, and uses thereof
WO2020221783A1 (en) Methods for pre-selection of neoepitopes
JP2022504635A (ja) ネオ抗原ベースの免疫療法のためのエピトープを標的化する方法およびシステム
US20220296642A1 (en) Methods of Making Therapeutic T Lymphocytes
HK40013532B (zh) 致免疫性的癌症特异抗原决定位的排名系统
HK40013532A (en) Ranking system for immunogenic cancer-specific epitopes
RU2826184C2 (ru) Способ отбора неоэпитопов
Spellman et al. Enhancing the Breadth and Efficacy of Therapeutic Vaccines for Breast Cancer